Insulet Corporation $PODD Shares Sold by Credit Agricole S A

Key Points

• Credit Agricole S A reduced its holdings in Insulet Corporation (NASDAQ:PODD) by 34.7%, selling 7,450 shares, resulting in ownership of 13,995 shares valued at $3,675,000.
• Multiple hedge funds have modified their positions in Insulet, with First Trust Advisors LP increasing its stake by 71.0% to 144,913 shares worth $37.83 million.
• Insulet reported an earnings per share (EPS) of $1.17 for the last quarter, surpassing estimates by 25 cents, with revenues reaching $649.1 million, which indicates a year-over-year increase of 32.9%.

Credit Agricole S A cut its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 34.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 13,995 shares of the medical instruments supplier's stock after selling 7,450 shares during the quarter. Credit Agricole S A's holdings in Insulet were worth $3,675,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of PODD. Mariner LLC increased its position in shares of Insulet by 8.1% during the 4th quarter. Mariner LLC now owns 6,727 shares of the medical instruments supplier's stock valued at $1,756,000 after purchasing an additional 505 shares during the period. Jump Financial LLC acquired a new position in shares of Insulet during the 4th quarter valued at $393,000. First Trust Advisors LP increased its position in shares of Insulet by 71.0% during the 4th quarter. First Trust Advisors LP now owns 144,913 shares of the medical instruments supplier's stock valued at $37,832,000 after purchasing an additional 60,187 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Insulet by 42.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 289,507 shares of the medical instruments supplier's stock valued at $75,588,000 after purchasing an additional 86,505 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in shares of Insulet by 65.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,332 shares of the medical instruments supplier's stock valued at $870,000 after purchasing an additional 1,323 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PODD. Canaccord Genuity Group lifted their price target on Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Barclays lifted their target price on Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a report on Thursday. Oppenheimer lifted their target price on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Truist Financial started coverage on Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 target price on the stock. Finally, Citigroup restated a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Sixteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $332.71.

Insulet Price Performance

PODD opened at $330.77 on Friday. The stock has a market cap of $23.28 billion, a price-to-earnings ratio of 100.54, a PEG ratio of 2.75 and a beta of 1.35. Insulet Corporation has a 1 year low of $180.31 and a 1 year high of $334.18. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock has a fifty day moving average price of $300.94 and a 200 day moving average price of $285.90.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business's revenue for the quarter was up 32.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.